Emerging cell therapy DA01 with BlueRock Therapeutics

https://is1-ssl.mzstatic.com/image/thumb/Podcasts114/v4/04/0f/c5/040fc53b-5094-22b3-3bd9-fe55262ca652/mza_4907689939715544408.jpg/600x600bb.jpg

Parkinson’s in Perspective

McGill Students for Parkinson's Awareness

6 episodes

1 week ago

Run by students from McGill University's Students for Parkinson's Awareness club, we interview leading researcher in the field of Neurodegeneration to bring our audience awareness of recent, innovative research findings on the origins, progression, and treatment of Parkinson's Disease

Medicine

Health & Fitness

RSS

All content for Parkinson’s in Perspective is the property of McGill Students for Parkinson's Awareness and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo400/9906693/9906693-1602773578218-ecf6e05b8d054.jpg

Emerging cell therapy DA01 with BlueRock Therapeutics

Parkinson’s in Perspective

31 minutes 57 seconds

3 years ago

Emerging cell therapy DA01 with BlueRock Therapeutics

Join us as we discuss BlueRock Therapeutic's new cell therapy DA01 currently in phase I clinical trials. Dr. Fasano and Dr. Enayetallah break down how this therapy has the potential to revolutionize the Parkinson's treatment landscape by providing tonic dopamine release and addressing underlying neuron degeneration.

Learn more about the clinical trial here.

Access the transcript here.